Breakthrough: ExpreS2ion launches first unique cell line for enhanced efficacy of vaccines and immunotherapy
After several years of research and development, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the launch of a new tailormade S2 cell line, HighMan-S2™. This is the first member of ExpreS2ion’s new functionally modified S2 product line, GlycoX-S2™, which utilises and expands the advantages of the ExpreS2 platform.For several years, ExpreS[2]ion has been working on the development of adding functional modifications to its powerful ExpreS[2] platform. This makes the introduction of the new HighMan-S2™ cell line an important